UK pharma giant GSK announced a $10.6 billion acquisition of cancer drugmaker Nuvalent, marking a major bet on precision oncology following FDA priority review

Legend Biotech reported that its LB2501, a potential first-in-class in vivo CD19/CD20 dual-targeting CAR-T therapy, achieved 100% response rate at the highest d

Clinical trial data showed a cancer vaccine reduced melanoma risk by 49% after five years, representing a significant advance in mRNA-based immunotherapy for so

Intellia completed the first Phase 3 trial of in vivo CRISPR therapy (lonvo-z) for hereditary angioedema, advancing gene-editing medicine toward commercial viab

Life Biosciences began the first human clinical trials testing age-reversal therapies targeting glaucoma through gene therapy approaches, marking a milestone in

Parabilis Medicines raised $770.5 million in its IPO and surged 58% on debut, breaking biotech records for largest first-day and opening-day gains.

Eli Lilly's retatrutide, a dual GLP-1/GIP receptor agonist, achieved record weight-loss results and is on track for FDA filing in obesity treatment.

AstraZeneca received FDA approval for TRUQAP combination therapy in prostate cancer, expanding the company's precision oncology portfolio with a targeted precis

Researchers demonstrated a CRISPR enzyme capable of precisely targeting and shredding DNA in cancer mutations previously considered undruggable, opening new the

Roche inked a $2.3 billion deal for a blood cancer drug, driving a biotech stock up 10% on the partnership agreement.

The FDA approved Sanofi's Tzield (teplizumab) for stage 3 type 1 diabetes in children, marking the first disease-modifying therapy for the autoimmune condition.

Tango Therapeutics reported positive Phase 2 data in pancreatic cancer, driving stock gains following the trial's clinical proof-of-concept.

An AI-designed universal vaccine targeting broad pathogenic threats advanced through Phase 1 human testing, potentially laying groundwork for pandemic preparedn

Nuvalent received FDA priority review designation for its lung cancer therapy, bolstering its value before GSK's $10.6 billion takeover completion.

A London-based biotech company initiated clinical trials of an oral drug designed to prevent cytokine storms, a dangerous immune response in cancer therapy pati

Eli Lilly unveiled first clinical data for the JAK inhibitor acquired in its $2.3 billion Ajax Pharmaceuticals deal, showing rapid pharmacodynamic response.

Rocket Pharma reaped $180 million from selling its FDA priority review voucher, a regulatory asset accelerating drug review timelines.

The UK approved Wegovy oral formulation for obesity, marking a major shift toward convenient pill-based GLP-1 receptor agonist therapy.